NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Buy
54
LFCR Quote, Financials, Valuation and Earnings
Last price:
$7.04
Seasonality move
:
6.07%
Day range:
$7.03 - $7.36
52-week range:
$3.68 - $8.90
Dividend yield:
0%
P/E ratio:
144.60x
P/S ratio:
1.99x
P/B ratio:
15.52x
Volume:
761.7K
Avg. volume:
225.3K
1-year change:
18.52%
Market cap:
$266.3M
Revenue:
$128.3M
EPS (TTM):
$0.23
Analysts' Opinion
-
Consensus RatingLifecore Biomedical has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, Lifecore Biomedical has an estimated upside of 10.65% from its current price of $7.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $7.23.
Fair Value
-
According to the consensus of 0 analysts, Lifecore Biomedical has 10.65% upside to fair value with a price target of -- per share.
LFCR vs. S&P 500
-
Over the past 5 trading days, Lifecore Biomedical has underperformed the S&P 500 by -3.07% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Lifecore Biomedical does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Lifecore Biomedical has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Lifecore Biomedical reported revenues of $37.9M.
Earnings Growth
-
Lifecore Biomedical earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Lifecore Biomedical reported earnings per share of -$0.23.
Enterprise value:
388.7M
EV / Invested capital:
--
Price / LTM sales:
1.99x
EV / EBIT:
15.36x
EV / Revenue:
3.03x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-44.22x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
11.44x
Gross Profit (TTM):
$41.9M
Return On Assets:
4.82%
Net Income Margin (TTM):
9.37%
Return On Equity:
475.5%
Return On Invested Capital:
10.53%
Operating Margin:
7.62%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2023-08-31 | 2024-08-31 | |
| Income Statement | ||||||
| Revenue | $125.7M | $104.1M | $128.4M | $24.5M | $24.7M | |
| Gross Profit | $41M | $24.7M | $44.5M | $2.7M | $5.4M | |
| Operating Income | -$4.5M | -$24M | -$9.7M | -$8.6M | -$11.1M | |
| EBITDA | $13.4M | -$40.5M | $34M | -$6.4M | -$8.9M | |
| Diluted EPS | -$3.36 | -$3.17 | $0.05 | -$0.35 | -$0.53 | |
| Period Ending | 2020-08-31 | 2021-08-31 | 2022-08-31 | 2023-08-31 | 2024-08-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $147.4M | $142.4M | $116.6M | $82.8M | $74.2M | |
| Total Assets | $506.2M | $445.6M | $285.8M | $245.6M | $246.8M | |
| Current Liabilities | $153.7M | $103.7M | $83.1M | $35.4M | $40.5M | |
| Total Liabilities | $285M | $251.8M | $188.9M | $259.2M | $250.8M | |
| Total Equity | $221.2M | $193.9M | $96.9M | -$13.6M | -$3.9M | |
| Total Debt | $173.9M | $155.8M | $142.6M | $107.9M | $127.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-08-31 | 2023-08-31 | 2024-08-31 | 2023-08-31 | 2024-08-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$24.5M | -$24.7M | $7.5M | -$8.3M | -$643K | |
| Cash From Investing | $41.5M | -$9.6M | -$16.3M | -$5.1M | -$3.4M | |
| Cash From Financing | -$14.2M | $38.7M | $5.7M | $2.9M | $1.1M | |
| Free Cash Flow | -$49.9M | -$47.8M | -$8.8M | -$13.4M | -$4M | |
LFCR
Sector
Market Cap
$266.3M
$43.9M
Price % of 52-Week High
81.24%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
18.53%
-29.11%
Beta (5-Year)
0.988
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$7.43
200-day SMA
Buy
Level
$5.86
Bollinger Bands (100)
Buy
Level
4.76 - 6.88
Chaikin Money Flow
Buy
Level
59.9M
20-day SMA
Sell
Level
$7.40
Relative Strength Index (RSI14)
Buy
Level
52.07
ADX Line
Buy
Level
7.14
Williams %R
Neutral
Level
-63.1068
50-day SMA
Buy
Level
$6.50
MACD (12, 26)
Buy
Level
0.18
25-day Aroon Oscillator
Buy
Level
8
On Balance Volume
Neutral
Level
60.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.5863)
Sell
CA Score
(Annual)
Level (-2.0082)
Buy
Beneish M-Score
(Annual)
Level (-2.2366)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.3166)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
Stock Forecast FAQ
In the current month, LFCR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LFCR average analyst price target in the past 3 months is --.
-
Where Will Lifecore Biomedical Stock Be In 1 Year?
According to analysts, the consensus estimate is that Lifecore Biomedical share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Lifecore Biomedical?
Analysts are divided on their view about Lifecore Biomedical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Lifecore Biomedical is a Sell and believe this share price will drop from its current level to --.
-
What Is Lifecore Biomedical's Price Target?
The price target for Lifecore Biomedical over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LFCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Lifecore Biomedical is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LFCR?
You can purchase shares of Lifecore Biomedical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Lifecore Biomedical shares.
-
What Is The Lifecore Biomedical Share Price Today?
Lifecore Biomedical was last trading at $7.04 per share. This represents the most recent stock quote for Lifecore Biomedical. Yesterday, Lifecore Biomedical closed at $7.23 per share.
-
How To Buy Lifecore Biomedical Stock Online?
In order to purchase Lifecore Biomedical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 6.77% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 15% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.74% over the past day.
